Table 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Authors

Kyoichi Okishio (ORCID: https://orcid.org/0000-0002-6348-1302)
Hiroki Izumi (ORCID: https://orcid.org/0000-0002-9566-4859)
Kohei Shitara (ORCID: https://orcid.org/0000-0001-5196-3630)
Hisashi Hosaka
Kunihiro Tsuji (ORCID: https://orcid.org/0000-0001-7463-7272)
Yukiya Narita (ORCID: https://orcid.org/0000-0002-8018-0077)
Motohiro Tamiya (ORCID: https://orcid.org/0000-0001-6529-3092)
Hiroki Hara (ORCID: https://orcid.org/0000-0003-3881-9815)
Nobuhiko Seki (ORCID: https://orcid.org/0000-0002-6562-1137)
Akihito Tsuji (ORCID: https://orcid.org/0000-0003-4034-1945)
Yasunori Ushida
Toshifumi Yamaguchi (ORCID: https://orcid.org/0000-0003-1399-1918)
Hideaki Suna (ORCID: https://orcid.org/0000-0001-9202-316X)
Kensei Yamaguchi (ORCID: https://orcid.org/0000-0001-6887-5709)
Katsunori Shinozaki (ORCID: https://orcid.org/0000-0003-0596-3423)
Hiroshi Tanaka (ORCID: https://orcid.org/0000-0002-8003-7326)
Yosuke Tamura (ORCID: https://orcid.org/0009-0000-0513-2860)
Naohiro Watanabe
Takeshi Shiraishi (ORCID: https://orcid.org/0000-0001-9558-3576)

Publication Details

Published: 2025-10-13
DOI: https://doi.org/10.1158/2767-9764.30344808
Primary Topic: Cancer Immunotherapy and Biomarkers
Type: article
Field-Weighted Citation Impact: 0.00

Table 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Kyoichi Okishio, Hiroki Izumi, Kohei Shitara, Hisashi Hosaka, Kunihiro Tsuji, Yukiya Narita, Motohiro Tamiya, Hiroki Hara, Nobuhiko Seki, Akihito Tsuji, Yasunori Ushida, Toshifumi Yamaguchi, Hideaki Suna, Kensei Yamaguchi, Katsunori Shinozaki, Hiroshi Tanaka, Yosuke Tamura, Naohiro Watanabe, Takeshi Shiraishi

October 13, 2025article en

Table 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Authors

Publication Details

Table 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Table 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study

Abstract

Ask Laika to Summarize, Analyze, and Connect papers live on the map.